The Future of Obesity Care Beyond GLP-1 Drugs

The future of obesity treatment extends far beyond popular GLP-1 receptor agonist medications such as semaglutide (Wegovy, Ozempic, Rybelsus) and tirzepatide (Mounjaro, Zepbound), incorporating personalized therapies and advanced procedures. Published on July 8, 2026, in the American Gastroenterological Association journal Gastroenterology, a new commentary titled 'Revisiting POWER in the GLP-1 Age' updates the 2017 Practice Guide on Obesity and Weight Management, Education, and Resources (POWER) framework to reflect rapid clinical advancements. The authors emphasize shifting from a body mass index (BMI)-centric model to viewing obesity as a complex, chronic, and systemic disease requiring comprehensive multidisciplinary management. Modern clinical approaches now strategically combine anti-obesity medications with advanced endoscopic bariatric and metabolic therapies, such as endoscopic sleeve gastroplasty, alongside traditional bariatric surgery to achieve superior and longer-lasting patient outcomes. Precision medicine and genetics are highlighted as emerging frontiers that will enable clinicians to tailor treatments specifically to individual patient profiles, maximizing efficacy and minimizing adverse effects. Furthermore, the updated framework underscores the expanding role of gastroenterologists and hepatologists in managing obesity-related comorbidities like metabolic dysfunction-associated steatotic liver disease (MASLD), gastroesophageal reflux disease (GERD), and gallbladder disease. For healthcare providers and patients, these advancements signal a transition toward integrated, multi-modal care strategies rather than reliance on single-agent pharmaceutical solutions. Clinicians should adopt multidisciplinary treatment models that integrate pharmacotherapy, procedural interventions, and personalized genetic insights to effectively combat the global chronic obesity epidemic.